Regenxbio said its Duchenne muscular dystrophy gene therapy RGX-202 met the bar in a pivotal trial, producing sufficiently high levels of a miniaturized muscle protein and paving the way for an FDA submission. The company framed the result as meeting criteria consistent with an accelerated approval pathway. The update arrives after a period of market pressure tied to earlier clinical uncertainties and setbacks for the platform’s FDA prospects. Regenxbio’s next steps now focus on submission timing and addressing safety and confirmatory requirements expected for gene therapies in DMD. For the field, the readout reinforces that durable microdystrophin expression remains the key translational marker under discussion across competing DMD gene therapy programs.